Chemours Company (the) · NYSE:CC

Chemours Company (the) — Q3 2026 Earnings Presentation

27 slides from Chemours Company (the)'s earnings presentation, Nov 3, 2026

  1. Slide 1: Q3 2026 Earnings Presentation

    Slide 1: Q3 2026 Earnings Presentation

    Q3 2026 EARNINGS PRESENTATION November 3, 2026

  2. Slide 2: Safe Harbor Statement and Other Matters

    Slide 2: Safe Harbor Statement and Other Matters

    Safe Harbor Statement and Other Matters This presentation contains forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which involve risks and uncertainties. Forward-looking statements provide current exp

  3. Slide 3: Third Quarter 2026 Highlights

    Slide 3: Third Quarter 2026 Highlights

    Third Quarter 2026 Highlights Generated $1.5B in Net Sales and $200M in Adjusted EBITDA, supported by a ~10% increase in YoY TT pricing, paired with positive product mix shift in APM APM Performance Solutions net sales grew 26% YoY, underscoring momentum and mix shift towards high-value end markets

  4. Slide 4: Third Quarter 2026 Financial Summary

    Slide 4: Third Quarter 2026 Financial Summary

    Third Quarter 2026 Financial Summary ($ in millions unless otherwise noted; excludes per share amounts) 3Q26 3Q25 Y-o-Y ∆ 2Q26 Q-o-Q ∆ Net Sales $1,540 $1,495 $45 $1,591 ($51) Net (Loss) / Income1 $196 $46 $150 ($274) $470 Adj. Net Income 2 $31 $26 $5 $64 ($33) EPS 3 $1.29 $0.31 $0.98 ($1.81) $3.10

  5. Slide 5: Adjusted EBITDA Bridge: 3Q26 versus 3Q25

    Slide 5: Adjusted EBITDA Bridge: 3Q26 versus 3Q25

    Adjusted EBITDA Bridge: 3Q26 versus 3Q25 ($ in millions) ($25) ($39) ($4) $79 $189 $200 3Q25 Price Volume Cost/Other Currency 3Q26 Price Impacts: $79 million due to higher pricing across the three primary segments, with strength in TiO2 pricing tied to the three disclosed pricing actions since Decem

  6. Slide 6: Quarterly Segment Summary

    Slide 6: Quarterly Segment Summary

    Quarterly Segment Summary ($ in millions unless otherwise noted) Net Sales TSS TT APM $468 $560 $510 $672 $612 $680 $354 $311 $337 3Q24 3Q25 3Q26 3Q24 3Q25 3Q26 3Q24 3Q25 3Q26 Adjusted EBITDA and Margin (%) TSS TT APM $139 $194 $136 $78 $25 $85 $38 $14 $24 3Q24 3Q25 3Q26 3Q24 3Q25 3Q26 3Q24 3Q25 3Q2

  7. Slide 7: Liquidity Position as of September 30, 2026

    Slide 7: Liquidity Position as of September 30, 2026

    Liquidity Position as of September 30, 2026 ($ in millions unless otherwise noted) Total Liquidity 8 $1.7B Gross Debt $3.9B Net Debt 9 $3.2B TTM Net Leverage 10 4.3x $801 $723 ($51) ($13) ($7) $103 Restricted $52 Restricted $149 $671 $698 Unrestricted Unrestricted 2Q26 Cash Balance 5 Operating Cash

  8. Slide 8: Strategic Progress

    Slide 8: Strategic Progress

    STRATEGIC PROGRESS PATHWAY TO THRIVE

  9. Slide 9: Our Strategy

    Slide 9: Our Strategy

    Our Strategy PATHWAY TO THRIVE Operational Enabling Portfolio Strengthening Excellence Growth Management the Long-Term ❑Manufacturing excellence as a basis for success ❑Investing smartly in selected ❑Holistic portfolio analysis ❑Measurable progress on growth projects focused on distinct value resolv

  10. Slide 10: Progress Achieved to Date

    Slide 10: Progress Achieved to Date

    Progress Achieved to Date PATHWAY TO THRIVE Operational Enabling Portfolio Strengthening Excellence Growth Management the Long-Term ✓ Notable progress against the ✓ Launched Chemours’ liquid ✓ Progressed APM European asset ✓ Announced settlement with State of $250M of run-rate savings by end cooling

  11. Slide 11: Introducing: Faizeon

    Slide 11: Introducing: Faizeon

    Introducing: ` Faizeon 100 Faizeon 110 Faizeon 200 Faizeon 220 Faizeon 500 Retrofit deployments Low-pressure direct-to-chip Performance / environmental balance Maximum thermal performance Two-phase immersion cooling Lowest-pressure profile Intermediate boiling point Medium-pressure operation Advance

  12. Slide 12: Strengthening the Long-Term: Resolving Legacy Liabilities

    Slide 12: Strengthening the Long-Term: Resolving Legacy Liabilities

    Strengthening the Long-Term: Resolving Legacy Liabilities Continued Progress 2017: January 2021: June 2023: December 2024: June 2026: Priorities for Resolving Remaining Legacy 1st Ohio MDL MOU with Corteva, EID, DuPont and U.S. Public Water System 3rd Ohio MDL Announced Settlement Settlement Chemour

  13. Slide 13: Fourth Quarter Guidance

    Slide 13: Fourth Quarter Guidance

    FOURTH QUARTER GUIDANCE

  14. Slide 14: Fourth Quarter and Full Year 2026 Guidance

    Slide 14: Fourth Quarter and Full Year 2026 Guidance

    Fourth Quarter and Full Year 2026 Guidance Sequential Business Outlook: Fourth Quarter 2026 Outlook Full Year 2026 Outlook  Consolidated o Net Sales: Expected to decrease in the (10%) to (5%) range sequentially o Adjusted EBITDA: Expected to range between $160 million and $185 million o Corporate E

  15. Slide 15: Appendix

    Slide 15: Appendix

    APPENDIX 15

  16. Slide 16: TSS Segment Net Sales and Adjusted EBITDA

    Slide 16: TSS Segment Net Sales and Adjusted EBITDA

    TSS Segment Net Sales and Adjusted EBITDA (Unaudited) ($ in millions) ($ in millions) % of total Net Sales $560 FP&O $510 17% ($2) $(48) FP&O FreonTM 24% Refrig. 17% FreonTM Refrig. 20% 3Q25 % total 3Q26 % total refrigerants: refrigerants: OpteonTM Freon = 20% Freon = 26% Refrigerants Opteon = Opteo

  17. Slide 17: TT Segment Net Sales and Adjusted EBITDA

    Slide 17: TT Segment Net Sales and Adjusted EBITDA

    TT Segment Net Sales and Adjusted EBITDA (Unaudited) ($ in millions) ($ in millions) $680 $612 Minerals 4% $9 Minerals 3% $58 TiO2 TiO2 96% 97% $85 $25 3Q25 Price/Currency Volume 3Q26 3Q25 Price/Currency Volume Cost/Other 3Q26 Net Sales: The increase was driven by a 10% increase in global pricing an

  18. Slide 18: APM Segment Net Sales and Adjusted EBITDA

    Slide 18: APM Segment Net Sales and Adjusted EBITDA

    APM Segment Net Sales and Adjusted EBITDA (Unaudited) ($ in millions) ($ in millions) % of total Net Sales $337 $311 $8 Performance $18 Performance Solutions Solutions 39% 45% Advanced Advanced Materials Materials $24 61% 55% $14 3Q25 Price/Currency Volume 3Q26 3Q25 Price/Currency Volume Cost/Other

  19. Slide 19: Segment Net Sales

    Slide 19: Segment Net Sales

    Segment Net Sales (Unaudited) 2024 2025 2026 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Net sales by product group and segment TM Opteon refrigerants $ 200 $ 227 $ 205 $ 178 $ 279 $ 375 $ 368 $ 243 $ 313 $ 337 $ 287 TM Freon refrigerants 173 173 146 124 97 123 98 113 162 150 100 Foam, propellants, and other 8

  20. Slide 20: Segment Net Sales by Region

    Slide 20: Segment Net Sales by Region

    Segment Net Sales by Region (Unaudited) 2024 2025 2026 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Net sales by geographic region North America: Thermal & Specialized Solutions $ 271 $ 308 $ 256 $ 194 $ 233 $ 336 $ 316 $ 241 $ 326 $ 340 $ 268 Titanium Technologies 246 274 270 236 267 282 252 221 235 267 282 Ad

  21. Slide 21: Segment Net Sales & Adjusted EBITDA

    Slide 21: Segment Net Sales & Adjusted EBITDA

    Segment Net Sales & Adjusted EBITDA (Unaudited) 2024 2025 2026 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Segment Net Sales Thermal & Specialized Solutions $ 454 $ 519 $ 468 $ 390 $ 466 $ 597 $ 560 $ 444 $ 568 $ 591 $ 510 Titanium Technologies 592 676 672 632 597 657 612 561 559 661 680 Advanced Performance M

  22. Slide 22: GAAP Net Income to Adjusted Net Income and Adjusted EBITDA Reconciliation

    Slide 22: GAAP Net Income to Adjusted Net Income and Adjusted EBITDA Reconciliation

    GAAP Net Income (Loss) Attributable to Chemours to Adjusted Net Income and Adjusted EBITDA Reconciliation (Unaudited) GAAP Net Leverage Ratio to Non-GAAP Net Leverage Ratio (Page 1/2) ($ in millions except per share amounts) Three Months Ended Three Months Ended Twelve Months Ended September 30, Jun

  23. Slide 23: GAAP Net Income to Adjusted Net Income and Adjusted EBITDA Reconciliation (2/2)

    Slide 23: GAAP Net Income to Adjusted Net Income and Adjusted EBITDA Reconciliation (2/2)

    GAAP Net Income (Loss) Attributable to Chemours to Adjusted Net Income and Adjusted EBITDA Reconciliation (Unaudited) GAAP Net Leverage Ratio to Non-GAAP Net Leverage Ratio (Page 2/2) ($ in millions except per share amounts) Three Months Ended Three Months Ended Twelve Months Ended September 30, Jun

  24. Slide 24: Operating Cash Flow to Free Cash Flows Reconciliation

    Slide 24: Operating Cash Flow to Free Cash Flows Reconciliation

    GAAP Cash Flow Provided by Operating Activities to Free Cash Flows and Free Cash Flow Conversion Reconciliation (1) Three Months Ended Nine Months Ended September 30, June 30, September 30, 2026 2025 2026 2026 2025 Cash flows provided by (used for) operating activities $ 149 $ 146 $ 158 $ 263 $ 127

  25. Slide 25: 2026 Estimated Operating Cash Flow to Free Cash Flows

    Slide 25: 2026 Estimated Operating Cash Flow to Free Cash Flows

    2026 Estimated GAAP Cash Flow Provided by Operating Activities to Estimated Free Cash Flows and Estimated Free Cash Flow Conversion Reconciliation (1) (2) Estimated Year Ended December 31, 2026 Low High Cash flows provided by operating activities $ 340 $ 390 Less: Purchases of property, plant, and e

  26. Slide 26: 2026 Estimated Net Loss to Adjusted Net Income and Adjusted EBITDA

    Slide 26: 2026 Estimated Net Loss to Adjusted Net Income and Adjusted EBITDA

    2026 Estimated GAAP Net Loss Attributable to Chemours to Estimated Adjusted Net Income and Estimated Adjusted EBITDA Reconciliation (1) (Estimated) Year Ending December 31, 2026 Low High Net loss attributable to Chemours $ (100) $ (90) Restructuring, transaction, and other costs, net (2) 210 210 Adj

  27. Slide 27: 2026 Chemours. All Rights Reserved

    Slide 27: 2026 Chemours. All Rights Reserved

    ® 2026 CHEMOURS. ALL RIGHTS RESERVED​

Source: 6ix earnings call

More decks from Chemours Company (the)

All 80 Chemours Company (the) decks